drugset / Trial / NCT06019507
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.
Timeline
- Start
- 2022-06-29
- Primary completion
- 2026-06
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Siplizumab | Monoclonal antibody | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | MMF | Unknown | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | TAC | Unknown | — | — |
Indications
No indication recorded.